{
    "id": 6778,
    "fullName": "EGFR exon 19 ins",
    "impact": "insertion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR exon 19 insertions are in-frame insertions within the kinase domain of Egfr (PMID: 22190593). Exon 19 insertions result in increased Egfr kinase activity and cell transformation in culture, and are associated with sensitivity to Egfr tyrosine kinase inhibitors (PMID: 22190593).",
            "references": [
                {
                    "id": 439,
                    "pubMedId": 22190593,
                    "title": "EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22190593"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "exon 19 ins",
    "createDate": "05/29/2015",
    "updateDate": "02/28/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17064,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Iressa (gefitinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as exon 19 insertions (NCCN.org).",
            "molecularProfile": {
                "id": 6633,
                "profileName": "EGFR exon 19 ins"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17063,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vizimpro (dacomitinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as exon 19 insertions (NCCN.org).",
            "molecularProfile": {
                "id": 6633,
                "profileName": "EGFR exon 19 ins"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17065,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tagrisso (osimertinib) is included in guidelines as preferred first-line or as subsequent therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as exon 19 insertions (NCCN.org).",
            "molecularProfile": {
                "id": 6633,
                "profileName": "EGFR exon 19 ins"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17061,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tarceva (erlotinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as exon 19 insertions (NCCN.org).",
            "molecularProfile": {
                "id": 6633,
                "profileName": "EGFR exon 19 ins"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17062,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Gilotrif (afatinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as exon 19 insertions (NCCN.org).",
            "molecularProfile": {
                "id": 6633,
                "profileName": "EGFR exon 19 ins"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6633,
            "profileName": "EGFR exon 19 ins",
            "profileTreatmentApproaches": [
                {
                    "id": 19744,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR exon 19 ins"
                },
                {
                    "id": 19746,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR exon 19 ins"
                },
                {
                    "id": 19747,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR exon 19 ins"
                },
                {
                    "id": 19748,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR exon 19 ins"
                },
                {
                    "id": 19745,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR exon 19 ins"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}